Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 67Lymphoma 55Multiple Myeloma 54Breast Neoplasms 52Neoplasm Metastasis 48Lung Neoplasms 47Prostatic Neoplasms 46Ovarian Neoplasms 39Leukemia, Myeloid, Acute 39Melanoma 37Carcinoma, Non-Small-Cell Lung 37Hematologic Neoplasms 35Colorectal Neoplasms 33Pancreatic Neoplasms 29Glioma 28Lymphoma, Non-Hodgkin 26Urinary Bladder Neoplasms 25Sarcoma 25Carcinoma, Renal Cell 25Brain Neoplasms 24Neuroblastoma 21Myelodysplastic Syndromes 21Triple Negative Breast Neoplasms 19Fallopian Tube Neoplasms 19Stomach Neoplasms 18Leukemia, Lymphocytic, Chronic, B-Cell 18Small Cell Lung Carcinoma 17Colonic Neoplasms 17Burkitt Lymphoma 17Squamous Cell Carcinoma of Head and Neck 16

Interventions

plerixafor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Agammaglobulinemia × 90 days × Clear all
NCT00967785 2026-05-22

A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
20 enrolled

Agammaglobulinemia, Immunologic Deficiency Syndromes, Infections, Leukopenia, Neutropenia, Warts

Data powered by HemOnc (CC BY 4.0) Colophon âš¡